

A signed statement by the applicant that the research work under reference has not been given any award. The applicant should also indicate the extent of the contribution of the others associated with the research and he/she should clearly acknowledge his/her achievements (Max: 500 KB)

I certify that research work under reference (1-14 mentioned below) has not been given any award. Reference 1-3 are the specifically highlighted for this award for which authors contribution is provided in red font.

1. Roy, Rizvi ZA, Clarke A, Macdonald F, Pandey A, Zaiss D, Dr. Simon KA, **Awasthi A**. EGFR-HIF1 α signaling positively regulates the differentiation of IL-9 producing T helper cells. **Nature Communication** **2021**, 12(1):3182. doi: 10.1038/s41467-021-23042-x

Author contributions

S.R. conceived, planned, designed, performed the experiments, collected and analyzed the data. Z.A.R. and F.M. performed the experiments. A.J.C. helped in performing metabolomics. A.P. provided assistance in bioinformatics analysis. D.M.W.Z. provided *Egfr^{flox/flox}XCd4^{cre}* mice. A.K.S. provided suggestions for the study. D.M.W.Z., A.K.S. and A.J.C. provided critical inputs in the manuscript. **A.A.** conceptualized, designed and supervised the study. S.R. and **A.A.** wrote the manuscript.

2. Rizvi ZA, Dalal R, Sadhu S, Kumar Y, Kumar S, Gupta SK, Tripathy MR, Rathore DK, **Awasthi A**. High salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity. **Science Advances** **2021**, 7(37):eabg5016. doi: 10.1126/sciadv.abg5016.

Author contributions

Conceived, designed, and supervised the study: **A.A.** Designed and performed the experiments: Z.A.R. and R.D. Animal experiments: Z.A.R. and R.D. FACS: Z.A.R., R.D., and D.K.R. Metabolomics: Z.A.R., Y.K., and S.K.G. qPCR: Z.A.R. and M.R.T. ELISA: Z.A.R. Metagenomics analysis: S.K. Analyzed the data: Z.A.R., R.D., S.S., and D.R. Contributed reagents/materials/analysis tools: **A.A.** Wrote the manuscript: Z.A.R. and **A.A.**

3. Thiruvengadam R, **Awasthi A**, Medigeshi GR, Bhattacharya S, Mani S, Sivasubbu S, Shrivastava S, Samal S, Murugesan DR, Desiraju BK, Kshetrapal P, Pandey R, Scaria V, Malik PK, Taneja J, Binayke A, Vohra T, Zaheer A, Rathore D, Khan NA, Shaman H, Ahmed S, Kumar R, Deshpande S, Subramani C, Wadhwa N, Gupta N, Pandey AK, Bhattacharya J, Agrawal A, Vratil S, Bhatnagar S, Garg PK. Cellular Immune Responses are Preserved and may Contribute to Vaccine Effectiveness Despite Reduced Virus Neutralization Against Infection due to SARS-CoV-2 B.1.617.2 Variant. **Lancet Infectious Disease** **2021**, accepted, in press

Author contributions

PKG conceptualized the overall study. ShB, RT and NW designed the study for clinical objectives; **AA**, GM, AnA, SB and SM designed the study for laboratory objectives; **AA**, AB, TV, AZ, DR designed, performed and analysed T cells assays; 398 RT, NW, DRM, PKM, JT, AKP, SB, SM, AB, TV, AZ, DR, NAK, HS, SrS, RP, VS, AnA, CS and SV conducted clinical and laboratory experiments; TS, SS, PK, RK, JB, PKM, JT, AKP and NG provided resources; BKD, RT, DRM, **AA**, GM, SrS, RP and VS, conducted data analyses; PKG, RT, **AA**, GM, SS and TS accessed and verified the data, compiled the results and wrote the manuscript; all authors reviewed the manuscript.

4. Sadhu S, Rizvi ZA, Pandey RP, Dalal R, Rathore DK, Kumar B, Pandey M, Kumar Y, Goel R, Maiti TK, Tiwari A, Pandey AK, **Awasthi A**. EGFR-HIF1 α axis is essential for the intracellular survival of *Salmonella*. **Front Immunol.** **2021**, 12:648710. doi: 10.3389/fimmu.2021.648710.
5. Vishwakarma P, Yadav N, Rizvi ZA, Khan NA, Chiranjivi A, Shrivastava T, Bansal M, Dwivedi P, Kumar R, **Awasthi A**, Ahmed S, Samal S. Characterization of SARS-CoV2 Spike Protein



Synthetic Peptides as potential targets for vaccine and therapeutics. **Front Immunol.** 2021, 12:613045. doi: 10.3389/fimmu.2021.613045.

6. Chauhan S, Rathore DK, Lacroix-Desmazes S, Gupta N, **Awasthi A**, Vrati S, Kalia M. Japanese encephalitis virus infected human monocyte-derived dendritic cells activate a transcriptional network leading to an antiviral inflammatory response. **Front Immunol.** 2021, 12:638694. doi: 10.3389/fimmu.2021.638694.
7. Ganneru B, Jogdand H, Dharam VK, Mulugu N, Prasad B S, Srinivas VK, Ella K, Ravikrishnan R, **Awasthi A**, Jose J, Rao P, Kumar D, Abraham P, Yadav P, Sapkal G, Shete A, Deshpande GR, Mohandas S, Basu A, Gupta N, Bhargava B, Mohan K, Ella R. Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152. **iScience** 2021, 24 (4):102298. doi: 10.1016/j.isci.2021.102298
8. Lin X, Gaudino S, Roy S, Castillo P, Elsegeiny W, Wakabayashi N, Oury TD, Pociask D, Chen K, **Awasthi A**, Kolls JK and Kumar P. Nrf2 differentially regulates IL-22 and IL-17A response in CD4+ T cells through Ahr and SOD3 axis. **Journal of Immunology** 2021, 206 (7); 1540-1548; doi: 10.4049/jimmunol.1900656.
9. Yadav N, Vishwakarma P, Khatri R, Siddiqui G, **Awasthi A**, Ahmed S, Samal S. Comparative Immunogenicity analysis of Intra dermal and Intra muscular administration of SARS-CoV2 RBD epitope peptide-based Immunogen. **Microbes and Infection** 2021, 23(4-5):104843. doi: 10.1016/j.micinf.2021.104843.
10. Shrivastava T, Singh B, Rizvi ZA, Verma R, Goswami S, Vishwakarma P, Jakhar K, Sonar S, Mani S, Bhattacharyya S, **Awasthi A**, Surjit M. Comparative immunomodulatory evaluation of the receptor binding domain of SARS CoV-2 spike protein; a potential vaccine candidate, imparts potent humoral and Th1 type of immune response in a mouse model. **Front Immunol.** 2021, 12:641447. doi: 10.3389/fimmu.2021.641447.
11. Rizvi ZA, Dalal R, Sadhu S, Kumar Y, Shrivastava T, Gupta SK, Agarwal S, Tripathy MR, Yadav AK, Medigeshi GR, Pandey AK, Samal S, Asthana S, **Awasthi A**. Immunological and cardiovascular pathologies associated with SARS-CoV-2 infection in golden syrian hamster. **BiorXiv preprint** 2021
12. Rizvi ZA, Tripathy MR, Sharma N, Goswami S, Srikanth N, Sastry JLN, Mani S, Surjit M, **Awasthi A***, Dikshit M. Effect of prophylactic use of intra-nasal oil formulation in the hamster model of Covid19. **Frontiers in Pharmacology** 2021, accepted, in press. ***Co-corresponding author**
13. Mittal L, Tonk RK, **Awasthi A**, Asthana S. Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach. **Arch Biochem Biophys.** 2021, 713:109059. doi: 10.1016/j.abb.2021.109059
14. Thiruvengadam R, Binayke A, **Awasthi A**, SARS-CoV-2 delta variant – a persistent threat to the effectiveness of vaccines. **Lancet Infectious Disease** 2021, accepted, in press

